HCPCS Q5147: Aflibercept-ayyh (Pavblu) 1 mg Injection
HCPCS Level II code Q5147 designates a 1 mg dose of aflibercept-ayyh (Pavblu), a biosimilar anti-VEGF agent administered by injection for ophthalmic indications. This code identifies the specific biosimilar product and enables standardized reporting of medication use and billing for intravitreal therapies that target retinal vascular disease. Nationally, precise coding for biosimilar ophthalmic injectables matters for product tracking, formulary management, and reimbursement consistency across payers.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of what Q5147 represents clinically and operationally, payer coverage considerations, common billing modifiers, and the typical site-of-service context. The publication summarizes billing benchmarks where available, highlights relevant policy updates affecting biosimilar ophthalmic agents, and situates Q5147 within clinical workflow for outpatient ophthalmology clinics and ambulatory surgical centers.
This summary is intended to help coding professionals, practice administrators, and policy analysts understand the role of HCPCS Level II code Q5147 in medical billing, formulary decisions, and encounter documentation for intravitreal anti-VEGF therapy.
Customize your policy alerts
Sign up for hcpcs Q5147 policy alerts
Get alerted when payer policies referencing Q5147 are released or updated.
Monitor payer policy activity
Billing Code Overview
HCPCS Level II code Q5147 represents an injection of aflibercept-ayyh (Pavblu), biosimilar, 1 mg. The service is an intravitreal or ocular injection of an anti-VEGF biosimilar used in ophthalmic care for retinal vascular conditions. The service type is an ophthalmic injectable medication administration, typically performed in an outpatient ophthalmology clinic or ambulatory surgical setting.